OpenLobby.EU
Explore

European Academy of Dermatology and Venereology

EADV

The EADV is a non-profit-making organisation whose objectives are: (A) The advancement of excellence in clinical care, research, education and training in the fields of Dermatology and Venereology. (B) The funding and the operation of an Academy for the purpose of providing the highest quality of advanced medical training in Dermatology and Venereology and related fields of medicine, science and research. (C) The promotion of the highest standards of clinical care in the aforementioned specialties. (D) The maintenance and enhancement of high standards in professions related to Dermatology and Venereology and public health services and other professions or practices that the Academy may from time to time consider relevant. (E) The education of the public and of patients, particularly those with cutaneous or venereal diseases, and advocacy on their behalf. (F) The preparation, editing, publication and circulation of such papers, books, journals or other literary or ele (...)

Lobbying Activity

Meeting with Tomislav Sokol (Member of the European Parliament, Rapporteur)

9 Mar 2023 · European Health Data Space - EHDS

Response to Cancer Screening Recommendation

22 Feb 2022

(Please see full statement enclosed) There is an epidemic of skin cancer (melanoma, basal cell carcinoma, squamous cell carcinoma) that significantly influences patient quality of life and survival. Skin cancer, the most common cancer, is also very expensive to treat with newer innovative therapies. For both reasons, it is a significant economic burden for national health systems that will only worsen as incidence increases. A disproportionate burden of skin cancer deaths and morbidity falls on individuals ages 65 and above. Therefore, all patients ages 65 and above (an easy way to identify high-risk) should receive a baseline skin exam by a qualified and appropriately trained physician. Ιndividuals in this age group may require a biannual skin exam unless there are specific high-risk factors that indicate a different screening interval. An appropriately constructed and validated risk-adjusted screening program for patients at medium to high risk can be cost-effective and feasible (with screening intervals adjusted to an individual risk assessment prior to the start of screening). Clinical evaluation of patients by appropriately trained HCPs with the aid of dermoscopy can reduce patient morbidity through earlier diagnosis of all types of skin cancer, reduce unnecessary biopsies, and drive down health care costs. Further research is needed in the use of biomarkers, genetic markers and new technologies (AI) to optimize skin cancer screening.
Read full response